Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
1995 1
1996 1
2010 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Effect of the phosphodiesterase inhibitor UK 61260 on human myocardial inotropy and diastolic relaxation.
Schwinger RH, Böhm M, La Rosée K, Schmidt U, Erdmann E. Schwinger RH, et al. J Cardiovasc Pharmacol. 1992 Jun;19(6):966-74. doi: 10.1097/00005344-199206000-00019. J Cardiovasc Pharmacol. 1992. PMID: 1376820
UK 61260 increased (p less than 0.01) +T and -T, resulting in a shortening of twitch time. As judged from the EC50 values, UK 61260 increased FOC more potently than MIL. The effectiveness of OUA and Ca2+ in increasing developed tension in human failing …
UK 61260 increased (p less than 0.01) +T and -T, resulting in a shortening of twitch time. As judged from the EC50 values, …
Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
Remme WJ, van der Ent M, Bartels GL, van Schelven D, van Hoogenhuyze DC, Krauss XH, Kruijssen HA, Storm CJ. Remme WJ, et al. Cardiovasc Drugs Ther. 1996 May;10(2):137-44. doi: 10.1007/BF00823591. Cardiovasc Drugs Ther. 1996. PMID: 8842505 Clinical Trial.
Nanterinone (UK-61,260) is a novel positive inotropic and balanced-type vasodilating drug, only partially based on phosphodiesterase III inhibition. ...Hemodynamic measurements were carried out before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 8, 12, and 24 hours after administration …
Nanterinone (UK-61,260) is a novel positive inotropic and balanced-type vasodilating drug, only partially based on phosphodiesterase …